Search research articles
Contact Us
Filters
Showing results (161-170 of 184) with videos related to
Page
of 19
Sort By:
Anticancer Research
|
December 29, 2010
CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes
Amanda Nickles Fader, Nabila Rasool, Susan A J Vaziri, et al.
Gynecologic Oncology
|
March 6, 2014
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study
Susana M Campos, William E Brady, Katherine M Moxley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 27, 2010
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer
Ignace Vergote, Neil J Finkler, James B Hall, et al.
Gynecologic Oncology
|
August 29, 2009
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
Amanda Nickles Fader, David Starks, Paola A Gehrig, et al.
Gynecologic Oncology
|
August 21, 2016
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis
Kathleen N Moore, James J Java, Katrina N Slaughter, et al.
Journal of Radiosurgery and SBRT
|
April 26, 2021
Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experience
Timothy D Smile, Chandana A Reddy, George Qiao-Guan, et al.
Gynecologic Oncology
|
August 28, 2012
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
Robert L Coleman, Michael W Sill, Heather A Lankes, et al.
Gynecologic Oncology
|
August 4, 2017
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Amanda N Fader, Jennifer Bergstrom, Amelia Jernigan, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Gynecologic Oncology
|
January 17, 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study
Vivian E von Gruenigen, Helen Q Huang, Jan H Beumer, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 184) with videos related to
Sort By:
Page
of 19
Anticancer Research
|
December 29, 2010
CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes
Amanda Nickles Fader, Nabila Rasool, Susan A J Vaziri, et al.
Gynecologic Oncology
|
March 6, 2014
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study
Susana M Campos, William E Brady, Katherine M Moxley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 27, 2010
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer
Ignace Vergote, Neil J Finkler, James B Hall, et al.
Gynecologic Oncology
|
August 29, 2009
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
Amanda Nickles Fader, David Starks, Paola A Gehrig, et al.
Gynecologic Oncology
|
August 21, 2016
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis
Kathleen N Moore, James J Java, Katrina N Slaughter, et al.
Journal of Radiosurgery and SBRT
|
April 26, 2021
Stereotactic body radiotherapy for the treatment of oligometastatic gynecological malignancy in the abdomen and pelvis: A single-institution experience
Timothy D Smile, Chandana A Reddy, George Qiao-Guan, et al.
Gynecologic Oncology
|
August 28, 2012
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
Robert L Coleman, Michael W Sill, Heather A Lankes, et al.
Gynecologic Oncology
|
August 4, 2017
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Amanda N Fader, Jennifer Bergstrom, Amelia Jernigan, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Gynecologic Oncology
|
January 17, 2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study
Vivian E von Gruenigen, Helen Q Huang, Jan H Beumer, et al.
Page
of 19